Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma
Source abstract
Abstract
In tumor treatment, the highly disordered vascular system and lack of accumulation of chemotherapeutic drugs in tumors severely limit the therapeutic role of nanocarriers. Smaller drug-containing nanoparticles (NPs) can better penetrate the tumor but are easily removed, which severely limits the tumor-killing properties of the drug. The chemotherapeutic medication doxorubicin (DOX) is highly toxic to the heart, but this toxicity can be effectively mitigated and the combined anticancer effect can be enhanced by clinically incorporating curcumin (CUR) as part of the dual therapy. We designed a small-molecule peptide, Pep1, containing a targeting peptide (CREKA) and a pH-responsive moiety. These NPs can target the blood vessels in tumor microthrombi and undergo a morphological shift in the tumor microenvironment. This process enhances the penetration and accumulation of drugs, ultimately improving the effectiveness of cancer treatment. In vitro and in vivo experiments demonstrated that this morphological transformation allowed rapid and effective drug release into tumors, the effective inhibition of tumor angiogenesis, and the promotion of tumor cell apoptosis, thus effectively killing tumor cells. Our findings provide a novel and simple approach to morphologically transforming nanocarriers in cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Nanoplatforms for cancer theranostics · Biochemical effects in animals
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Global burden of primary liver cancer in 2020 and predictions to 204010.1016/j.jhep.2022.08.021 ↗
2. Challenges in liver cancer and possible treatment approaches10.1016/j.bbcan.2019.188314 ↗
3. 2026P - the clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin10.1093/annonc/mdz269.043 ↗
4. Polysaccharide-based nanocarriers for efficient transvascular drug delivery10.1016/j.jconrel.2022.12.051 ↗
5. Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers10.1021/acsami.8b21609 ↗
6. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs10.1002/adma.201401554 ↗
7. pH-Sensitive nanoparticles based on amphiphilic imidazole/cholesterol modified hydroxyethyl starch for tumor chemotherapy10.1016/j.carbpol.2021.118827 ↗
8. Construction of dually responsive nanotransformers with nanosphere-nanofiber-nanosphere transition for overcoming the size paradox of anticancer nanodrugs10.1021/acsnano.9b05749 ↗
9. Pair correlation microscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release10.1038/nnano.2016.160 ↗
10. Dual-responsive nanoparticles with transformable shape and reversible charge for amplified chemo-photodynamic therapy of breast cancer10.1016/j.apsb.2022.03.010 ↗
11. Self-oxygenation of tissues orchestrates full-thickness vascularization of living implants
12. Shape transformable strategies for drug delivery10.1002/adfm.202009765 ↗
13. GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy10.1016/j.apsb.2020.10.009 ↗
14. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer10.1016/j.jconrel.2020.02.043 ↗
15. Plasma amine oxidase-induced nanoparticle-to-nanofiber geometric transformation of an peptide for drug encapsulation and enhanced bactericidal activity10.1021/acsami.9b21296 ↗
16. Enzyme-induced transformable peptide nanocarriers with enhanced drug permeability and retention to improve tumor nanotherapy efficacy10.1021/acsami.1c17917 ↗
17. The acidic tumor microenvironment as a driver of cancer10.1146/annurev-physiol-021119-034627 ↗
18. The acidic tumor microenvironment: a target for smart cancer nano-theranostics10.1093/nsr/nwx062 ↗
19. Self-enhanced acoustic impedance difference strategy for detecting the acidic tumor microenvironment10.1021/acsnano.1c10173 ↗
20. Multi-transformable nanocarrier with tumor extracellular acidity-activated charge reversal, size reduction and ligand reemergence for in vitro efficient doxorubicin loading and delivery10.1016/j.msec.2020.111250 ↗
21. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence10.1186/s12929-023-00915-5 ↗
22. Normalizing function of tumor vessels: progress, opportunities, and challenges10.1146/annurev-physiol-020518-114700 ↗
23. Recent progress in advanced hydrogel-based embolic agents: from rational design strategies to improved endovascular embolization
24. Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy10.1007/s11426-022-1347-9 ↗
25. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy10.1007/s10456-022-09863-4 ↗
26. Nanoparticle-induced vascular blockade in human prostate cancer10.1182/blood-2010-03-274258 ↗
27. Recent advances of CREKA peptide-based nanoplatforms in biomedical applications10.1186/s12951-023-01827-0 ↗
28. A bioinspired nanoprobe with multilevel responsive T (1) -weighted MR signal-amplification illuminates ultrasmall metastases
29. Hyaluronic acid-based nanoplatforms for Doxorubicin: a review of stimuli-responsive carriers, co-delivery and resistance suppression10.1016/j.carbpol.2021.118491 ↗
30. Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy10.1016/j.jconrel.2022.12.048 ↗
31. A micelle-based stage-by-stage impelled system for efficient doxorubicin delivery
32. An efficient carbon-based drug delivery system for cancer therapy through the nucleus targeting and mitochondria mediated apoptotic pathway10.1002/smtd.202100539 ↗
33. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care10.1016/j.biopha.2021.112503 ↗
34. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment10.1016/j.addr.2022.114445 ↗
35. Curcumin induced oxidative stress causes autophagy and apoptosis in bovine leucocytes transformed by Theileria annulata10.1038/s41420-019-0180-8 ↗
36. Angiogenic hyaluronic acid hydrogels with curcumin-coated magnetic nanoparticles for tissue repair10.1021/acsami.1c19889 ↗
37. A modular coassembly approach to all-in-one multifunctional nanoplatform for synergistic codelivery of doxorubicin and curcumin10.3390/nano8030167 ↗
38. Rational design of cancer nanomedicine for simultaneous stealth surface and enhanced cellular uptake
39. Nanoparticulation of prodrug into medicines for cancer therapy10.1002/advs.202101454 ↗
40. Enzyme-induced morphological transformation of self-assembled peptide nanovehicles potentiates intratumoral aggregation and inhibits tumour immunosuppression10.1016/j.cej.2022.140466 ↗
41. Matrix metalloproteinase-2-induced morphologic transformation of self-assembled peptide nanocarriers inhibits tumor growth and metastasis10.1021/acsmaterialslett.2c01093 ↗
42. Rational design of ibuprofen-based redox-responsive anti-cancer polymeric drug delivery systems10.1007/s10853-022-07347-w ↗
43. Preparation, characterization and antioxidant properties of curcumin encapsulated chitosan/lignosulfonate micelles10.1016/j.carbpol.2021.119080 ↗
44. Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance10.3390/cancers11071026 ↗
45. Enzyme-instructed intracellular molecular self-assembly to boost activity of cisplatin against drug-resistant ovarian cancer cells10.1002/anie.201507157 ↗
46. Cancer cell-derived, drug-loaded nanovesicles induced by sulfhydryl-blocking for effective and safe cancer therapy10.1021/acsnano.8b05377 ↗
47. Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy10.1126/sciadv.aaw6081 ↗
48. Co-delivery of drugs and plasmid DNA for cancer therapy10.1016/j.addr.2015.10.014 ↗
49. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant10.1021/nl803487r ↗
50. Cholesterol-Modified amino-pullulan nanoparticles as a drug carrier: comparative study of cholesterol-modified carboxyethyl pullulan and pullulan nanoparticles10.3390/nano6090165 ↗
51. The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells
52. Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells10.1002/jps.21994 ↗
53. CRPC membrane-camouflaged, biomimetic nanosystem for overcoming castration-resistant prostate cancer by cellular vehicle-aided tumor targeting10.3390/ijms23073623 ↗
54. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds10.1002/med.21948 ↗
55. KCl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial-mesenchymal transition10.1158/0008-5472.CAN-07-2443 ↗
56. Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death10.1038/s41467-021-26613-0 ↗
57. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death10.1038/s41423-020-00630-3 ↗
58. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation10.1038/s41467-019-09397-2 ↗
59. An improved method in fabrication of smart dual-responsive nanogels for controlled release of doxorubicin and curcumin in HT-29 colon cancer cells10.1186/s12951-020-00764-6 ↗
60. Tumoural activation of TLR3-SLIT2 axis in endothelium drives metastasis10.1038/s41586-020-2774-y ↗
61. Intracellular delivery of nanocarriers and targeting to subcellular organelles10.1517/17425247.2015.1086745 ↗
62. Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma10.1186/s12943-017-0640-9 ↗
63. Fluorescence-guided fiber-optic micronavigation using microscopic identification of vascular boundary of liver segment and tumors10.7150/thno.45973 ↗
64. Extracellular vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport10.7150/ijbs.31605 ↗
65. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays10.1158/1078-0432.CCR-04-0021 ↗
66. IL-17A and CCL2 in blood serum and circulating neutrophils in patients with ovarian tumors10.1200/JCO.2021.39.15_suppl.e17536 ↗